Orforglipron
LY3502970, Orfo
The first oral GLP-1 that works as a plain small molecule. No injection, no fridge, and no fasting window before you take it.
Human trials
Investigational, but further along than anything else on this page. The FDA accepted Eli Lilly's application for chronic weight management in late 2025, and a separate diabetes filing is following. Not yet approved.
What it is
Orforglipron is a GLP-1 receptor agonist, same target as semaglutide. What makes it interesting is not the target but the molecule: it is a small molecule rather than a peptide, so your gut cannot digest it into uselessness before it reaches the bloodstream.
That sounds like a technicality. It is not. Every other drug in this class is either an injection or, in the case of oral semaglutide, a peptide bolted to an absorption enhancer that only works if you take it fasted, with a sip of water, and then wait half an hour. Orforglipron is a tablet you swallow whenever.
What the evidence shows
ATTAIN-1, the pivotal obesity trial, reported roughly 12.4% mean weight reduction at 72 weeks on the top dose, about 27 lb. ATTAIN-2, in people who also had type 2 diabetes, came in around 10.5% with HbA1c down 1.3 to 1.8 points.
Set that beside the injectables honestly:
| Route | Duration | Mean weight change | |
|---|---|---|---|
| Orforglipron 36 mg | Oral, daily | 72 wk | ~-12.4% |
| Semaglutide 2.4 mg | Injection, weekly | 68 wk | ~-14.9% |
| Tirzepatide 15 mg | Injection, weekly | 72 wk | ~-20.9% |
So it loses to both injectables on raw efficacy. In a head to head against oral semaglutide in diabetes it won on HbA1c by roughly half a point, which tells you where it actually competes: against the other pill, not against the needle.
Why it still matters
Adherence is where weight drugs go to die, and a daily tablet with no fridge, no needle and no fasting ritual removes three reasons people quit. Manufacturing a small molecule is also far cheaper and faster to scale than a peptide, which is the quiet reason analysts care about this one.
If you want the largest number, that is still tirzepatide or retatrutide. If you want something you will actually keep taking, the calculation changes.
Practical notes
- Titrate slowly. The GI profile looks like the rest of the class, and the same rule holds: escalation speed drives tolerability far more than the final dose.
- Do not stack it with another incretin. It occupies the same receptor. You would be adding side effects, not results.
- What is sold online is not this. No orforglipron has ever reached a pharmacy shelf. Anything offered as orforglipron today is grey-market material of unverified identity, and a small molecule is if anything easier to counterfeit convincingly than a peptide.
Side effects and warning signs
Commonly reported
- Nausea, vomiting, diarrhoea and constipation, worst during escalation
- Discontinuation for gastrointestinal reasons ran higher than placebo across the programme
- Reduced appetite firm enough that protein intake needs watching
Stop and get medical help
- Persistent severe abdominal pain radiating to the back, the usual pancreatitis presentation
- Right upper quadrant pain during rapid weight loss, which points at the gallbladder
- Any personal or family history of medullary thyroid carcinoma or MEN2
Sources
From the community
Discussion for this compound concentrates in r/GLP1 and r/Peptidesource.
No threads cached yet.
Reddit removed unauthenticated API access, so this section is populated by a build-time script using your own API credentials. Run pnpm fetch:reddit with REDDIT_CLIENT_ID and REDDIT_CLIENT_SECRET set.